1Garcia-Tsao G.Current management of the complications of the cirrhosis and portal hypertension:variceal hemorrhage,ascites and spontaneous bacterial peritonitis.Gastroenterology,2001,120:726-748.
2Rossle M,Siegerstetter V,Olschewski M,et al.How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts.Am J Gastroenterol,2001,96:3379-3383.
3Reynaert H,Thompson MG,Thomas T,et al.Hepatic stellate cells:role in microcirculation and pathophysiology of portal hypertension.Gut,2000,50:571-581.
4Chan CC,Wang SS,Lee FY,et al.Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats.Hepatology,2001,33:816-820.
5Garcia-Pagan JC,Villanueva C,Vila MC,et al.Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers.Gastroenterology,2001,121:908-914.
6Bellis L,Berzigotti A,Abraldes JG,et al.Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with Cirrhosis.Hepatology,2003,37:378-384.
7Reynaert H,Vaeyens F,Qin H,et al.Somatostatin suppresess endothelin-l-induced rat hepatic stellate cell contraction via somatostatin receptor subtype 1.Gastroenterology,2001,121:915-930.
8Merkel C,Marin R,Sacerdoti D.Long-term results of a clinical trial of Nadolol with or without Isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis.Hepatology,2000,31:324-329.
9Schepke M,Werner E,Biecker E,et al.Hemodynamic effects of the angiotensin Ⅱ receptor antagonist irbesartan in patients with cirrhosis and portal hypertension.Gastroenterology,2001,121:389-395.
10Escorsell A,Bordas JM,Feu F,et al.Endoscopic assessment of variceal volume and wall tension in cirrhotic patients:effects of pharmacological therapy.Gastroenterology,1997,113:1640-1646.
